Unknown

Dataset Information

Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial.


ABSTRACT:

Background

Current dosing practices for warfarin are empiric and result in the need for frequent dose changes as the international normalized ratio gets too high or too low. As a result, patients are put at increased risk for thromboembolism, bleeding, and premature discontinuation of anticoagulation therapy. Prior research has identified clinical and genetic factors that can alter warfarin dose requirements, but few randomized clinical trials have examined the utility of using clinical and genetic information to improve anticoagulation control or clinical outcomes among a large, diverse group of patients initiating warfarin.

Methods

The COAG trial is a multicenter, double-blind, randomized trial comparing 2 approaches to guiding warfarin therapy initiation: initiation of wa

SUBMITTER: Kimmel SE 

PROVIDER: S-EPMC4415273 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature